Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 4/20 | 0.52 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.45 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393449 | 1.00 | KAT6A (0.52) | KAT6AGSK3BPTPN1TAS1R3TAS1R1 | |
| SCHEMBL14023387 | 0.86 | GSK3B (0.48) | KAT6AGSK3BPTPN1 | |
| SCHEMBL15382733 | 0.85 | KAT6A (0.53) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL11778319 | 0.84 | GSK3B (0.51) | GSK3BPTPN1HDAC8HSD11B1 | |
| SCHEMBL13780117 | 0.84 | KAT6A (0.52) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL2094983 | 0.84 | KAT6A (0.52) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL311274 | 0.84 | KAT6A (0.52) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL2379136 | 0.84 | KAT6A (0.52) | KAT6AGSK3BTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29393793 | 0.84 | KAT6A (0.52) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| Hydrochloric Acid SCHEMBL22556728 | 0.83 | KAT6A (0.51) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| EP-4232448-B1 | AGONISTS OF FREE FATTY ACID RECEPTOR 1 AND THEIR USE IN DISEASES ASSOCIATED WITH SAID RECEPTOR | Halo Therapeutics Ltd (GB) | 2025-05-07 | — | — | EP | disclosed |
| EP-3956323-B1 | OXAZOLE AND OXADIAZOLE DERIVATIVES USEFUL AS AGONISTS OF FREE FATTY ACID RECEPTOR 1 | Halo Therapeutics Ltd (GB) | 2025-03-05 | — | — | EP | disclosed |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | PRISM MEDICINES, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | Ikena Oncology, Inc. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | Halo Therapeutics Ltd (GB) | 2024-05-16 | — | — | US | disclosed |
| EP-4265613-A1 | BENZENE RING COMPOUND AND USE THEREOF | Nanjing Shijiang Medicine Technology Co., Ltd (CN) | 2023-10-25 | — | — | EP | disclosed |
| EP-1152759-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| CN-1314899-A | Retinoid-associated receptor regulators | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-09-26 | — | — | CN | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1092711-A1 | RETINOID-ASSOCIATED RECEPTOR REGULATORS | Takeda Chemical Industries, Ltd. (JP) | 2001-04-18 | — | — | EP | disclosed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158382-A1 | Agonists Of Free Fatty Acid Receptor 1 And Their Use In Diseases Associated With Said Receptor | FFAR1, FFAR2, FFAR3 | KAT6A 3316/4885GSK3B 4031/4885PTPN1 991/4885 |
| US-20250011315-A1 | ARYL HYDROCARBON RECEPTOR (AHR) AGONISTS AND USES THEREOF | AHR, ARNT, HCAR1 | KAT6A 1142/4885GSK3B 3183/4885PTPN1 1910/4885 |
| US-12030876-B2 | Aryl hydrocarbon receptor (AHR) agonists and uses thereof | AHR, ARNT, HCAR1 | KAT6A 1142/4885GSK3B 3183/4885PTPN1 1910/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | KAT6A 449/4885GSK3B 3174/4885PTPN1 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.